| Symbol | PMN |
|---|---|
| Name | PROMIS NEUROSCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Canada |
| Telephone | 416-847-6898 |
| Fax | — |
| — | |
| Website | https://www.promisneurosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001374339 |
| Description | ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimers disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinsons disease, and dementia with Lewy bodies. It primarily operates in Canada. Additional info from NASDAQ: |
(30% Negative) PROMIS NEUROSCIENCES INC. (PMN) Reports Q3 2026 Financial Results
Read moreProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Read moreNew Form SCHEDULE 13G/A - ProMIS Neurosciences Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000902219-26-000224 <b>Size:</b> 17 KB
Read moreKaplan Johanne 🟢 acquired 2.3K shares of ProMIS Neurosciences Inc. (PMN) at $13.30 Transaction Date: Aug 05, 2026 | Filing ID: 092673
Read moreProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Read moreProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Read more(85% Positive) PROMIS NEUROSCIENCES INC. (PMN) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment
Read moreProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1bAlzheimer’s Disease Trial
Read moreProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
Read moreProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 inAlzheimer’s Disease
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06750432 | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Phase1 | Alzheimer Disease, Early Onset | Active_Not_Recruiting | 2024-12-13 | 2026-12-01 | ClinicalTrials.gov |
| NCT06105528 | A Phase 1a Study of PMN310 In Healthy Volunteers | Phase1 | Healthy Participants | Completed | 2023-11-18 | 2024-07-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06105528 |
| PMN310 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06105528 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| PMN310 | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| Placebo | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| PMN310 | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |